LifeCycle Pharma Increases Share Capital by 150,813 Shares as a Consequence of the Exercise of Employee Warrants
26-03-09 kl. 26/3 2009 09:00 | Veloxis Pharmaceuticals 0,90 (+4,65%)
Se flere nyheder om Veloxis Pharmaceuticals
LifeCycle Pharma A/S (CSE:LCP) has decided to increase its share capital by nom. 150,813 shares as a consequence of the exercise of warrants. The increase is executed without any pre-emption rights for the existing shareholders of the company or others.
The shares are subscribed in cash as follows: (1) Nom. 27,760 shares are subscribed against payment of DKK 6,0634 per share of nom. DKK 1. (2) Nom. 123,053 shares are subscribed against payment of DKK 6,4782 per share of nom. DKK 1. Gross proceeds to the company are DKK 964,929. The increase corresponds to approx. 0,27 % of the company's share capital after the increase. The new shares are ordinary bearer shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the date of the registration of the capital increase with the Commerce and Companies Agency. The new shares will be listed on the NASDAQ OMX Copenhagen after registration with the said agency. The company’s current share capital amounts to DKK 56,287,507 shares and will after the capital increase be DKK 56,438,320. The capital increase is expected to be finalized shortly. 
English PDF
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 0,90 |
|---|---|
| ÆNDRING | +0,04 (+4,65%) |
| ÅBEN | 0,87 |
| SIDSTE LUK | 0,86 |
| DEBAT | - |
 |
